Details of the Drug Combination

General Information of Drug Combination (ID: DC1ZVYZ)

Drug Combination Name
obeticholic acid Atorvastatin
Indication
Disease Entry Status REF
Nonalcoholic Steatohepatitis Phase 2 [1]
Component Drugs obeticholic acid   DM3Q1SM Atorvastatin   DMF28YC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of obeticholic acid
Disease Entry ICD 11 Status REF
Primary biliary cholangitis DB96.1 Approved [2]
Insomnia 7A00-7A0Z Clinical trial [3]
obeticholic acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Farnesoid X-activated receptor (FXR) TTS4UGC NR1H4_HUMAN Modulator [2]
------------------------------------------------------------------------------------
obeticholic acid Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Bile acid-CoA thioesterase (BAAT) DERA3OF BAAT_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
obeticholic acid Interacts with 230 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Very long chain fatty acid elongase 7 (ELOVL7) OT89NYVC ELOV7_HUMAN Increases Expression [8]
cTAGE family member 15 (CTAGE15) OTMOMQGH CTGEF_HUMAN Increases Expression [8]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) OTOMP6TH PK3CD_HUMAN Decreases Expression [8]
Nuclear receptor subfamily 5 group A member 2 (NR5A2) OTXAUJAS NR5A2_HUMAN Decreases Expression [8]
Suppressor of cytokine signaling 2 (SOCS2) OTBPNKJQ SOCS2_HUMAN Decreases Expression [8]
Copper chaperone for superoxide dismutase (CCS) OTXHT3QO CCS_HUMAN Decreases Expression [8]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Increases Expression [8]
Dual specificity mitogen-activated protein kinase kinase 7 (MAP2K7) OT1Q40TZ MP2K7_HUMAN Decreases Expression [8]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Decreases Expression [8]
Peroxisomal acyl-coenzyme A oxidase 3 (ACOX3) OTZEPVGF ACOX3_HUMAN Increases Expression [8]
Tapasin (TAPBP) OTL81AVZ TPSN_HUMAN Decreases Expression [8]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Decreases Expression [8]
Long-chain-fatty-acid--CoA ligase 4 (ACSL4) OTI71MUJ ACSL4_HUMAN Increases Expression [8]
Transcription factor Maf (MAF) OT1GR3IZ MAF_HUMAN Increases Expression [8]
Ribosomal protein S6 kinase alpha-5 (RPS6KA5) OTAVZJ3J KS6A5_HUMAN Decreases Expression [8]
Ribosomal protein S6 kinase alpha-4 (RPS6KA4) OTTK8MUO KS6A4_HUMAN Decreases Expression [8]
Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial (SLC25A12) OTB4YBVT S2512_HUMAN Decreases Expression [8]
Lathosterol oxidase (SC5D) OT41KMW4 SC5D_HUMAN Decreases Expression [8]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [8]
Fibroblast growth factor 19 (FGF19) OT2DVJWY FGF19_HUMAN Increases Expression [8]
Alcohol dehydrogenase 1C (ADH1C) OTO1DV7F ADH1G_HUMAN Decreases Expression [8]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases Expression [8]
Alpha-1-antitrypsin (SERPINA1) OTACYW9J A1AT_HUMAN Decreases Expression [8]
Alpha-2-macroglobulin (A2M) OTFTX90K A2MG_HUMAN Decreases Expression [8]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Decreases Expression [8]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Decreases Expression [8]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [8]
GTPase HRas (HRAS) OTWQN0DP RASH_HUMAN Decreases Expression [8]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Decreases Expression [8]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Expression [8]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Decreases Expression [8]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Decreases Expression [8]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Expression [8]
Apolipoprotein A-II (APOA2) OTQ3HGTC APOA2_HUMAN Increases Expression [8]
Apolipoprotein C-II (APOC2) OTLINYIQ APOC2_HUMAN Increases Expression [8]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Expression [8]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [8]
Albumin (ALB) OTVMM513 ALBU_HUMAN Decreases Expression [8]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Decreases Expression [8]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Decreases Expression [8]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Increases Expression [8]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Expression [8]
Phosphatidylcholine-sterol acyltransferase (LCAT) OTRLMLK0 LCAT_HUMAN Decreases Expression [8]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Decreases Expression [8]
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) OTBPMIMW G3P_HUMAN Decreases Expression [8]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [8]
Fructose-bisphosphate aldolase B (ALDOB) OT7FR69A ALDOB_HUMAN Decreases Expression [8]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Decreases Expression [8]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Expression [8]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Decreases Expression [8]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [8]
Alpha-enolase (ENO1) OTB1KWJS ENOA_HUMAN Decreases Expression [8]
Histone H2B type 1-J (H2BC11) OTGM083T H2B1J_HUMAN Decreases Expression [8]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Increases Expression [8]
Apolipoprotein(a) (LPA) OTRZLU9F APOA_HUMAN Decreases Expression [8]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [8]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Expression [8]
Steroid 21-hydroxylase (CYP21A2) OTN0UDVP CP21A_HUMAN Decreases Expression [8]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Decreases Expression [8]
Proto-oncogene tyrosine-protein kinase ROS (ROS1) OTDSKUGE ROS1_HUMAN Increases Expression [8]
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1) OTVKRET0 THIK_HUMAN Increases Expression [8]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Decreases Expression [8]
Fructose-1,6-bisphosphatase 1 (FBP1) OTQBANEP F16P1_HUMAN Decreases Expression [8]
Inhibin beta B chain (INHBB) OT2QLD11 INHBB_HUMAN Increases Expression [8]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Increases Expression [8]
Serum amyloid A-1 protein (SAA1) OTO2D8S0 SAA1_HUMAN Increases Expression [8]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [8]
Transforming growth factor beta-3 proprotein (TGFB3) OT2LOUQ1 TGFB3_HUMAN Increases Expression [8]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Expression [8]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Expression [8]
Hepatic triacylglycerol lipase (LIPC) OTZY5SC9 LIPC_HUMAN Decreases Expression [8]
Pyruvate carboxylase, mitochondrial (PC) OT6O0V51 PYC_HUMAN Decreases Expression [8]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Increases Expression [8]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [8]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Expression [8]
Beta-enolase (ENO3) OT3HYKYI ENOB_HUMAN Increases Expression [8]
Farnesyl pyrophosphate synthase (FDPS) OT6CKWV5 FPPS_HUMAN Decreases Expression [8]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (PFKFB1) OTTHX4NB F261_HUMAN Increases Expression [8]
Protein kinase C alpha type (PRKCA) OT5UWNRD KPCA_HUMAN Increases Expression [8]
Transcription factor JunB (JUNB) OTG2JXV5 JUNB_HUMAN Decreases Expression [8]
Glutathione peroxidase 2 (GPX2) OTXI2NTI GPX2_HUMAN Decreases Expression [8]
Syndecan-1 (SDC1) OTWKRVZC SDC1_HUMAN Increases Expression [8]
Retinoic acid receptor RXR-alpha (RXRA) OTP1TBDM RXRA_HUMAN Decreases Expression [8]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases Expression [8]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Increases Expression [8]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Expression [8]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Increases Expression [8]
Glycerol-3-phosphate dehydrogenase , cytoplasmic (GPD1) OTQW7TMB GPDA_HUMAN Decreases Expression [8]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Increases Expression [8]
Fibroblast growth factor receptor 4 (FGFR4) OTRQERG2 FGFR4_HUMAN Decreases Expression [8]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Increases Expression [8]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Decreases Expression [8]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Expression [8]
Peroxiredoxin-6 (PRDX6) OTS8KC8A PRDX6_HUMAN Decreases Expression [8]
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform (PPP2R1B) OTFIHQGD 2AAB_HUMAN Increases Expression [8]
Glutathione S-transferase theta-1 (GSTT1) OTRFMWBK GSTT1_HUMAN Increases Expression [8]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [8]
RAC-beta serine/threonine-protein kinase (AKT2) OTBB632K AKT2_HUMAN Decreases Expression [8]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Decreases Expression [8]
Glycerol kinase (GK) OTK2YRA0 GLPK_HUMAN Decreases Expression [8]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Decreases Expression [8]
Protein S100-A3 (S100A3) OTVIZJ2R S10A3_HUMAN Decreases Expression [8]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1) OTNWEJ5Y PCKGC_HUMAN Decreases Expression [8]
Insulin-like growth factor-binding protein complex acid labile subunit (IGFALS) OTTWCZYM ALS_HUMAN Decreases Expression [8]
Phosphoglucomutase-1 (PGM1) OT3VM4JX PGM1_HUMAN Decreases Expression [8]
TGF-beta receptor type-1 (TGFBR1) OT40S1SJ TGFR1_HUMAN Decreases Expression [8]
Sterol regulatory element-binding protein 1 (SREBF1) OTWBRPAI SRBP1_HUMAN Decreases Expression [8]
Interleukin-6 receptor subunit beta (IL6ST) OT1N9C70 IL6RB_HUMAN Decreases Expression [8]
Malate dehydrogenase, cytoplasmic (MDH1) OTJEO4E8 MDHC_HUMAN Increases Expression [8]
Mitogen-activated protein kinase kinase kinase 8 (MAP3K8) OTOZTA1F M3K8_HUMAN Increases Expression [8]
3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) OTGLVWOP THIM_HUMAN Increases Expression [8]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Decreases Expression [8]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Decreases Expression [8]
Lanosterol synthase (LSS) OT9W2SFH LSS_HUMAN Decreases Expression [8]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Decreases Expression [8]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Increases Expression [8]
Interleukin-1 receptor-associated kinase 1 (IRAK1) OT133G8J IRAK1_HUMAN Decreases Expression [8]
Aldo-keto reductase family 1 member D1 (AKR1D1) OTBDJ6RL AK1D1_HUMAN Decreases Expression [8]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6) OTK13JKC MP2K6_HUMAN Decreases Expression [8]
Tricarboxylate transport protein, mitochondrial (SLC25A1) OTIDXQ9F TXTP_HUMAN Decreases Expression [8]
Diphosphomevalonate decarboxylase (MVD) OTGEX4SR MVD1_HUMAN Decreases Expression [8]
Mitogen-activated protein kinase 12 (MAPK12) OTTCKE27 MK12_HUMAN Decreases Expression [8]
Glycogen synthase, liver (GYS2) OTCKIUYR GYS2_HUMAN Increases Expression [8]
Phospholipid transfer protein (PLTP) OTVJJO5Z PLTP_HUMAN Decreases Expression [8]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Decreases Expression [8]
3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 (HSD17B7) OTV7VOV3 DHB7_HUMAN Decreases Expression [8]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Decreases Expression [8]
Ras-related protein R-Ras2 (RRAS2) OT83NCEB RRAS2_HUMAN Increases Expression [8]
Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform (PPP2CB) OT24GMCM PP2AB_HUMAN Increases Expression [8]
Metallothionein-1H (MT1H) OT0MVBM6 MT1H_HUMAN Decreases Expression [8]
Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2) OT6HTSJT PGBM_HUMAN Decreases Expression [8]
Nuclear factor NF-kappa-B p100 subunit (NFKB2) OTS231V7 NFKB2_HUMAN Decreases Expression [8]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Decreases Expression [8]
Protein kinase C epsilon type (PRKCE) OT7J0P9L KPCE_HUMAN Increases Expression [8]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Decreases Expression [8]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Decreases Expression [8]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Increases Expression [8]
Mevalonate kinase (MVK) OTHJCUKT KIME_HUMAN Decreases Expression [8]
Peroxiredoxin-1 (PRDX1) OTZ3BEC4 PRDX1_HUMAN Decreases Expression [8]
Cytochrome P450 4F3 (CYP4F3) OTYNSQAM CP4F3_HUMAN Decreases Expression [8]
Adenylate cyclase type 1 (ADCY1) OTSLLFZO ADCY1_HUMAN Increases Expression [8]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Decreases Expression [8]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Expression [8]
TNF receptor-associated factor 2 (TRAF2) OT1MEZZN TRAF2_HUMAN Decreases Expression [8]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Increases Expression [8]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Decreases Expression [8]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Increases Expression [8]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [8]
Isopentenyl-diphosphate Delta-isomerase 1 (IDI1) OTGM06VJ IDI1_HUMAN Decreases Expression [8]
Phosphatidate phosphatase LPIN1 (LPIN1) OTQ75KF2 LPIN1_HUMAN Decreases Expression [8]
Delta(14)-sterol reductase LBR (LBR) OT1HG3HG LBR_HUMAN Decreases Expression [8]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Expression [8]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) OTM0A0DY ACOX1_HUMAN Increases Expression [8]
Ribosomal protein S6 kinase alpha-2 (RPS6KA2) OTIOYUSU KS6A2_HUMAN Increases Expression [8]
Transcription elongation factor A protein 2 (TCEA2) OT1OS9TY TCEA2_HUMAN Increases Expression [8]
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 (TAB1) OTPM6F85 TAB1_HUMAN Decreases Expression [8]
Mitogen-activated protein kinase 11 (MAPK11) OT0AS010 MK11_HUMAN Decreases Expression [8]
Methylsterol monooxygenase 1 (MSMO1) OTKV62RZ MSMO1_HUMAN Decreases Expression [8]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [8]
Dual specificity protein phosphatase 6 (DUSP6) OT4H6RKW DUS6_HUMAN Increases Expression [8]
Lanosterol 14-alpha demethylase (CYP51A1) OTAYHG9C CP51A_HUMAN Decreases Expression [8]
Meteorin-like protein (METRNL) OTB0DDL0 METRL_HUMAN Decreases Expression [8]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3) OTDMU3GP CR3L3_HUMAN Increases Expression [8]
Single Ig IL-1-related receptor (SIGIRR) OTNC3XFD SIGIR_HUMAN Decreases Expression [8]
Ultra-long-chain fatty acid omega-hydroxylase (CYP4F22) OTMNPZQL CP4FN_HUMAN Decreases Expression [8]
Vitamin D 25-hydroxylase (CYP2R1) OT0L1M1D CP2R1_HUMAN Increases Expression [8]
SUZ domain-containing protein 1 (SZRD1) OTJMEJWT SZRD1_HUMAN Increases Expression [8]
Cytochrome P450 2U1 (CYP2U1) OT6RXLXS CP2U1_HUMAN Increases Expression [8]
Tubulin epsilon and delta complex protein 1 (TEDC1) OT2RIGR7 TEDC1_HUMAN Decreases Expression [8]
ADAMTS-like protein 2 (ADAMTSL2) OTAXNV2U ATL2_HUMAN Decreases Expression [8]
60 kDa lysophospholipase (ASPG) OT5E2EKR LPP60_HUMAN Decreases Expression [8]
Organic solute transporter subunit alpha (SLC51A) OTDJRZ0P OSTA_HUMAN Increases Expression [8]
Organic solute transporter subunit beta (SLC51B) OT4WYPSR OSTB_HUMAN Increases Expression [8]
Na(+)/citrate cotransporter (SLC13A5) OTPH1TA7 S13A5_HUMAN Decreases Expression [8]
Leucine-rich repeat LGI family member 4 (LGI4) OTZGS8BN LGI4_HUMAN Increases Expression [8]
Neuropeptide W (NPW) OTO7MT28 NPW_HUMAN Decreases Expression [8]
Sodium-dependent lysophosphatidylcholine symporter 1 (MFSD2A) OTVG1VG0 NLS1_HUMAN Increases Expression [8]
Mixed lineage kinase domain-like protein (MLKL) OTDSLC81 MLKL_HUMAN Decreases Expression [8]
Scavenger receptor class B member 1 (SCARB1) OTAE1UA1 SCRB1_HUMAN Increases Expression [8]
Phosphatidate phosphatase LPIN2 (LPIN2) OTRRTMXX LPIN2_HUMAN Decreases Expression [8]
Caspase-10 (CASP10) OTE6J88E CASPA_HUMAN Increases Expression [8]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Expression [8]
Cyclic AMP-responsive element-binding protein 3-like protein 1 (CREB3L1) OT2JHIHM CR3L1_HUMAN Decreases Expression [8]
Diacylglycerol O-acyltransferase 2 (DGAT2) OTE5PDD0 DGAT2_HUMAN Decreases Expression [8]
Leukocyte receptor cluster member 8 (LENG8) OT6B5K2T LENG8_HUMAN Increases Expression [8]
Cytochrome P450 2S1 (CYP2S1) OTKHX4RF CP2S1_HUMAN Decreases Expression [8]
Peroxisomal acyl-coenzyme A oxidase 2 (ACOX2) OT3VH359 ACOX2_HUMAN Increases Expression [8]
Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) OTT3DOOL M3K14_HUMAN Decreases Expression [8]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) OTQR6ENW M3K5_HUMAN Decreases Expression [8]
Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial (ECSIT) OTJX1YC7 ECSIT_HUMAN Decreases Expression [8]
Receptor-transporting protein 3 (RTP3) OTZUDJ6Q RTP3_HUMAN Increases Expression [8]
Very long chain fatty acid elongase 1 (ELOVL1) OTIDTQ8R ELOV1_HUMAN Increases Expression [8]
Protein amnionless (AMN) OTS1TJXG AMNLS_HUMAN Decreases Expression [8]
Forkhead box protein P3 (FOXP3) OTA9Z9OC FOXP3_HUMAN Increases Expression [8]
3 beta-hydroxysteroid dehydrogenase type 7 (HSD3B7) OT2Y9IW4 3BHS7_HUMAN Decreases Expression [8]
Lck-interacting transmembrane adapter 1 (LIME1) OTJWUQSK LIME1_HUMAN Decreases Expression [8]
Very long chain fatty acid elongase 6 (ELOVL6) OTB26UJJ ELOV6_HUMAN Decreases Expression [8]
Cytochrome P450 3A43 (CYP3A43) OTMXADGA CP343_HUMAN Decreases Expression [8]
Cytochrome P450 4F11 (CYP4F11) OTHZ2GG2 CP4FB_HUMAN Decreases Expression [8]
Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM) OTR1XD9B GPAT1_HUMAN Decreases Expression [8]
Cytochrome P450 4F12 (CYP4F12) OTIUY7E6 CP4FC_HUMAN Decreases Expression [8]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Increases Expression [8]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5) OTNY3VMD PLCE_HUMAN Decreases Expression [8]
Very long chain fatty acid elongase 2 (ELOVL2) OTDAF6U3 ELOV2_HUMAN Increases Expression [8]
24-hydroxycholesterol 7-alpha-hydroxylase (CYP39A1) OTBAJT4I CP39A_HUMAN Decreases Expression [8]
Very-long-chain enoyl-CoA reductase (TECR) OT2NT4MV TECR_HUMAN Decreases Expression [8]
C5a anaphylatoxin chemotactic receptor 2 (C5AR2) OTP1Q82J C5AR2_HUMAN Decreases Expression [8]
7-dehydrocholesterol reductase (DHCR7) OTLILBUI DHCR7_HUMAN Increases Expression [8]
DnaJ homolog subfamily B member 11 (DNAJB11) OTDDK2SY DJB11_HUMAN Increases Expression [8]
Mitochondrial dicarboxylate carrier (SLC25A10) OTT8647H DIC_HUMAN Decreases Expression [8]
Cysteine-rich C-terminal protein 1 (CRCT1) OTPYME8V CRCT1_HUMAN Decreases Expression [8]
Fetuin-B (FETUB) OT7V07NI FETUB_HUMAN Increases Expression [8]
Polypyrimidine tract-binding protein 2 (PTBP2) OTF4S7NE PTBP2_HUMAN Decreases Expression [8]
Long-chain-fatty-acid--CoA ligase 6 (ACSL6) OT0TT8P8 ACSL6_HUMAN Increases Expression [8]
Long-chain-fatty-acid--CoA ligase 5 (ACSL5) OT3L9XO3 ACSL5_HUMAN Increases Expression [8]
Myocardin-related transcription factor B (MRTFB) OT9OXGS9 MRTFB_HUMAN Decreases Expression [8]
Carbonic anhydrase 14 (CA14) OT1TRKFN CAH14_HUMAN Increases Expression [8]
Transcription factor MafF (MAFF) OT9B7MX0 MAFF_HUMAN Increases Expression [8]
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1) OTRI4UR1 CP8B1_HUMAN Increases Expression [8]
Protein phosphatase 1 regulatory subunit 3C (PPP1R3C) OTEU05TX PPR3C_HUMAN Decreases Expression [8]
Long-chain fatty acid transport protein 5 (SLC27A5) OT4OK511 S27A5_HUMAN Decreases Expression [8]
Acyl-coenzyme A thioesterase 9, mitochondrial (ACOT9) OTBOQE6N ACOT9_HUMAN Increases Expression [8]
Chloride intracellular channel protein 4 (CLIC4) OT6KTPKD CLIC4_HUMAN Increases Expression [8]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Decreases Expression [8]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Increases Expression [11]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Secretion [12]
Cytochrome P450 7A1 (CYP7A1) OT8Z5KLD CP7A1_HUMAN Decreases Expression [11]
Hepatic sodium/bile acid cotransporter (SLC10A1) OTUJVMCL NTCP_HUMAN Decreases Expression [11]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [11]
Protein arginine N-methyltransferase 1 (PRMT1) OTN8GTXW ANM1_HUMAN Increases Activity [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 230 DOT(s)
Indication(s) of Atorvastatin
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [4]
Angina pectoris BA40 Approved [4]
Arteriosclerosis BD40 Approved [4]
Cardiovascular disease BA00-BE2Z Approved [5]
Coronary atherosclerosis N.A. Approved [4]
Hypercholesterolaemia 5C80.0 Approved [4]
Hyperlipidemia 5C80.Z Approved [6]
Hyperlipidemia, familial combined, LPL related N.A. Approved [4]
Hypertriglyceridemia 5C80.1 Approved [4]
Inflammation 1A00-CA43.1 Approved [4]
Non-insulin dependent diabetes 5A11 Approved [4]
Psoriasis EA90 Approved [4]
Type-1/2 diabetes 5A10-5A11 Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [7]
Stroke 8B20 Investigative [4]
Venous thromboembolism BD72 Investigative [4]
Atorvastatin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [16]
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) TTDJB68 N.A. Inhibitor [17]
------------------------------------------------------------------------------------
Atorvastatin Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [18]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [19]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [20]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [21]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [22]
Monocarboxylate transporter 1 (SLC16A1) DT342ZG MOT1_HUMAN Substrate [23]
Monocarboxylate transporter 2 (SLC16A7) DTLT3UG MOT2_HUMAN Substrate [24]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Atorvastatin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [25]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [26]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [27]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [28]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [29]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Atorvastatin Interacts with 93 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases ADR [31]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [32]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Expression [33]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [34]
Kinesin-like protein KIF6 (KIF6) OTDH3MR4 KIF6_HUMAN Increases Response To Substance [35]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Activity [36]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Expression [37]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [38]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [38]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [33]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Decreases Expression [33]
Angiopoietin-2 (ANGPT2) OTEQK65P ANGP2_HUMAN Increases Expression [13]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [13]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Expression [13]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [13]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Expression [13]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Activity [39]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [40]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [41]
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2) OTBL2W7R GTR2_HUMAN Decreases Expression [41]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [41]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [42]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Increases Expression [42]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Decreases Activity [43]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [44]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Increases Expression [34]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [45]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [14]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Affects Expression [42]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [46]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [47]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Affects Expression [42]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Increases Expression [46]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [48]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Expression [49]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [44]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [50]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [51]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [52]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [14]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Increases Expression [53]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Decreases Localization [54]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [55]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [56]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [51]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [56]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Decreases Expression [55]
Coagulation factor V (F5) OTDMZ3LT FA5_HUMAN Decreases Activity [43]
Bone morphogenetic protein 2 (BMP2) OT23T37S BMP2_HUMAN Increases Expression [46]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [51]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Increases Expression [14]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Decreases Expression [52]
Integrin alpha-X (ITGAX) OTOGIMHE ITAX_HUMAN Decreases Expression [55]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [42]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [56]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [56]
Interleukin-12 subunit alpha (IL12A) OTDQT8GI IL12A_HUMAN Decreases Expression [57]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [58]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [50]
Nicotinamide N-methyltransferase (NNMT) OTFM38GU NNMT_HUMAN Increases Expression [59]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [42]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [44]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [56]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [56]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [60]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [61]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Affects Localization [62]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [34]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [63]
Transforming protein RhoA (RHOA) OT6YOJ9N RHOA_HUMAN Decreases Activity [56]
Rho-related GTP-binding protein RhoB (RHOB) OTHQFQF7 RHOB_HUMAN Increases Expression [54]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [49]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [44]
CD83 antigen (CD83) OT1V4WQF CD83_HUMAN Decreases Expression [42]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [64]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [56]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Decreases Expression [65]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Localization [61]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Increases Activity [59]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [63]
Serum paraoxonase/arylesterase 2 (PON2) OT55NCTD PON2_HUMAN Increases Expression [66]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Decreases Expression [45]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [49]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [64]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Phosphorylation [59]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Response To Substance [50]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [67]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases ADR [31]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [68]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Increases Uptake [69]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Decreases Transport [70]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Increases Uptake [69]
Sister chromatid cohesion protein DCC1 (DSCC1) OTPUVLZT DCC1_HUMAN Affects Response To Substance [71]
------------------------------------------------------------------------------------
⏷ Show the Full List of 93 DOT(s)

References

1 ClinicalTrials.gov (NCT02633956) Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
2 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
3 Nuclear receptors and lipid physiology: opening the X-files. Science. 2001 Nov 30;294(5548):1866-70.
4 Atorvastatin FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945.
7 ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health.
8 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
9 UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chem Biol Interact. 2019 Sep 1;310:108745. doi: 10.1016/j.cbi.2019.108745. Epub 2019 Jul 9.
10 Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem. 1994 Jul 29;269(30):19375-9.
11 The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
12 Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011 Apr;60(4):463-72. doi: 10.1136/gut.2010.212159. Epub 2011 Jan 17.
13 Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
14 Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):481-90. doi: 10.1016/j.numecd.2008.10.003. Epub 2009 Jan 26.
15 Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
16 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
17 Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
18 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
19 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
20 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
21 FDA Drug Development and Drug Interactions
22 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
23 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
24 Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
25 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
27 Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
28 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
29 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
30 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
31 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
32 Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. 2005 Aug;60(8):747-53.
33 Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
34 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
35 [Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease]. Kardiologiia. 2011;51(9):4-12.
36 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
37 Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005 Feb;54(2):142-50.
38 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
39 The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
40 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
41 Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016 Jan 15;100:98-111.
42 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
43 Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. doi: 10.1111/j.1538-7836.2006.02165.x. Epub 2006 Aug 14.
44 Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.
45 Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011 Feb 3;146(3):319-25. doi: 10.1016/j.ijcard.2009.07.002. Epub 2009 Aug 3.
46 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007 Aug 15;101(6):1430-8. doi: 10.1002/jcb.21259.
47 Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 2005 Jul;20(4):133-6. doi: 10.1007/s00380-005-0833-9.
48 Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol. 2002 Jul;17(7):540-3. doi: 10.1007/s00467-002-0860-z. Epub 2002 May 25.
49 Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway. J Appl Toxicol. 2019 Oct;39(10):1394-1404. doi: 10.1002/jat.3825. Epub 2019 Aug 18.
50 Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010 Oct 1;70(19):7699-709. doi: 10.1158/0008-5472.CAN-10-1626. Epub 2010 Sep 28.
51 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
52 The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005 Dec 15;96(12):1699-704. doi: 10.1016/j.amjcard.2005.07.092. Epub 2005 Oct 28.
53 Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells. J Cardiovasc Pharmacol. 2003 Jan;41(1):89-96. doi: 10.1097/00005344-200301000-00012.
54 Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer. 2008 May 1;122(9):2115-24. doi: 10.1002/ijc.23315.
55 Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007;45(2):193-9.
56 RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006 Nov;13(11):1845-56. doi: 10.1038/sj.cdd.4401873. Epub 2006 Feb 10.
57 Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected]. Eur J Clin Invest. 2003 Jan;33(1):88-91. doi: 10.1046/j.1365-2362.2003.01105.x.
58 Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006 Jan;151(1):139. doi: 10.1016/j.ahj.2005.10.006.
59 Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. J Appl Toxicol. 2021 Jul;41(7):1076-1088. doi: 10.1002/jat.4094. Epub 2020 Oct 19.
60 Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol. 2004 Apr 7;43(7):1188-94. doi: 10.1016/j.jacc.2003.10.046.
61 Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
62 Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
63 Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
64 Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Can J Physiol Pharmacol. 2009 Nov;87(11):915-22. doi: 10.1139/y09-085.
65 Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol. 2011 Jul 15;662(1-3):9-14. doi: 10.1016/j.ejphar.2011.04.043. Epub 2011 May 1.
66 Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):175-80. doi: 10.1161/01.ATV.0000104011.88939.06. Epub 2003 Oct 30.
67 Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
68 Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
69 The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6.
70 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
71 Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Toxicol Appl Pharmacol. 2022 Oct 1;452:116169. doi: 10.1016/j.taap.2022.116169. Epub 2022 Aug 1.